2021
Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry
Lockshin B, Cronin A, Harrison R, McLean R, Anatale‐Tardiff L, Burge R, Zhu B, Malatestinic W, Atiya B, Murage M, Gallo G, Strober B, Van Voorhees A. Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry. Dermatologic Therapy 2021, 34: e14808. PMID: 33491259, PMCID: PMC8047872, DOI: 10.1111/dth.14808.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, Monoclonal, HumanizedFemaleHumansInterleukin-17MaleMiddle AgedPsoriasisRegistriesTumor Necrosis Factor InhibitorsConceptsCorrona Psoriasis RegistryIL-17 inhibitorsIL-17iTNF inhibitorsReal-world patientsDrug survivalHazard ratioPsoriasis RegistryDrug discontinuationDrug initiationLower riskBiologic experienceIxekizumab groupsPsO patientsSevere PsONaïve patientsMean ageIxekizumabPatientsReal-world settingDiscontinuationPsoriasisSurvivalRegistryInhibitors
2014
Tumor necrosis factor inhibitors in psoriasis: an update.
Kerdel F, Strober B. Tumor necrosis factor inhibitors in psoriasis: an update. Seminars In Cutaneous Medicine And Surgery 2014, 33: s31-6. PMID: 24979543, DOI: 10.12788/j.sder.0066.Peer-Reviewed Original ResearchConceptsTumor necrosis factorTNF inhibitorsNecrosis factor inhibitorsTreatment of psoriasisCertolizumab pegolPlaque psoriasisPsoriatic arthritisFactor inhibitorsClinical trialsNecrosis factorPsoriasisRecent evidenceInhibitorsEfficacyGolimumabInfliximabPegolAdalimumabEtanerceptArthritisImmunogenicity